PharmaSeq

Home Company Management & Directors

Management and Directors

Management

Wlodek Mandecki, Ph.D.
President and Chairman

Dr. Wlodek Mandecki is President, Chairman of the Board of Directors and Chief Scientific Officer of PharmaSeq, Inc. Dr. Mandecki received a B.S. in physics from the University of Warsaw, Poland, and a Ph.D. in biochemistry from the Polish Academy of Sciences. Dr. Mandecki performed his postdoctoral training at the University of California at Los Angeles, the University of Wisconsin at Madison, and the University of Colorado at Boulder. He was at Abbott Laboratories for 12 years, initially as a Group Leader and later as an R&D Manager in the Corporate Molecular Biology Department, Pharmaceutical Products Division and Abbott Diagnostics Division. Before founding PharmaSeq, Dr. Mandecki was Director of Molecular Biology at DGI Biotechnologies, a biotech start-up company in Edison, NJ. He is also Adjunct Professor at the Department of Microbiology and Molecular Genetics at the New Jersey Medical School of Rutgers University at Newark, NJ.

In addition to his accomplishments in the area of gene analysis, he has made important contributions in the area of gene regulation, expression and mutagenesis, protein structure-function, protein design and engineering, phage display and drug discovery. Dr. Mandecki has several patents and patent applications pending. He is an author of over sixty publications in peer reviewed scientific journals and has written several book chapters.

Richard G. Morris, Ph.D.
CEO

Dr. Richard Morris is Chief Executive Officer of PharmaSeq. He has over 35 year’s experience in the areas of biomedical instrumentation and biotechnology. Shortly after receiving his Ph.D. in biochemistry from the University of California, he began his career at Durrum Instruments (now Dionex Corp., now part of Thermo-Fisher). After many years of increasing responsibility at Dionex, Dr. Morris was promoted to Vice President of International Operations. He then became Vice President of Worldwide Sales at Molecular Dynamics (now part of GE Healthcare), where he was responsible for sales and service operations management, including subsidiaries in North America, Europe and the Pacific Rim. He then joined Sigma-Aldrich Corp. (St. Louis, MO) as President of Sigma-Aldrich Research. During his four years at this $800 million revenue division, he directed worldwide sales of catalog research products, and the organization and supervision of sales forces, marketing and associated services. In addition, he integrated multiple brands into the Research Division, created a national account strategy, instituted product management approval, and opened new markets for the company. Subsequently, he was President at CambridgeSoft Corp. (now part of Perkin-Elmer Corp.), a company specializing in desktop software solutions for chemical compound modeling. Dr. Morris has also consulted for a number of small and large biotechnology corporations.

Board of Directors

Dr. Wlodek Mandecki
Chairman
(background provided under Management)

Dr. Richard Morris
(background provided under Management)

Zbigniew Darzynkiewicz, M.D., Ph.D.

Zbigniew Darzynkiewicz, M.D., Ph.D., is the Director of the Brander Cancer Research Institute at the New York Medical College and the Professor of Medicine and Pathology at the same College. Formerly, Dr. Darzynkiewicz was the Professor of Cell Biology and Genetics at Cornell University Medical School, a Member of the Sloan-Kettering Institute for Cancer Research, the Head of the Experimental Cell Research Laboratory, and the Director of the Flow Cytometry Core Facility Network, all at the Sloan-Kettering Institute, New York. Dr. Darzynkiewicz is the Editor of Experimental Cell Research and Cell Proliferation and a Member of the Editorial Boards of nine other scientific journals. He is the past President of The Cell Kinetics Society and also past President of the International Society for Analytical Cytology (ISAC; with over 2,000 members from over 60 countries). Dr. Darzynkiewicz has authored 400 original publications and over 75 chapters and reviews in books devoted to the subject of cell growth, regulation of the cell cycle and apoptosis, and has authored and/or edited 11 books. He holds five US patents, several are pending. His publications have been cited over 9,000 times in the scientific literature. He consults several pharmaceutical companies and is on the Board of Scientific Advisors of the Alfacell Company (Bloomfield, NJ). Dr. Darzynkiewicz received his M.D. (with highest honors) in 1960 and his Ph.D. in 1966 from the Medical School of Warsaw, Warsaw, Poland. He completed his post-graduate studies at the State University of New York at Buffalo and the Medical Nobel Institute of Karolinska Institute, Stockholm, Sweden. Since 1974, he has been associated with the Sloan-Kettering Institute for Cancer Research, and since 1990, he has been with New York Medical College, Valhalla, New York.

 

Home Company Management & Directors